This webinar reviews the stages of biosimilar development, from purchase and characterization of the originator molecule to release of the finished biosimilar product to the regulated market, and discusses how manufacturers can use CROs to their best advantage. Different models for the relationship are covered with recommendations based on Charles River’s experience with multiple development programs.


  • Niall Dinwoodie, BSc MSc CChem MRSC QP (IMPs), Global Coordinator of Analytical Testing, Charles River

Please see the links below for the other webinars in the series:

MoA Reflecting Bioassays to Confirm Biosimilarity

The Role of Mass Spectrometry in Demonstrating Biosimilarity

Nonclinical and Clinical Bioanalytical Assay Requirements for Biosimilar Drug Development